ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 137 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2015. The put-call ratio across all filers is 8.04 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $2,219,000 | +24.6% | 37,810 | -0.7% | 2.93% | +17.0% |
| Q3 2017 | $1,781,000 | -24.2% | 38,062 | -41.7% | 2.51% | -17.2% |
| Q2 2017 | $2,349,000 | -41.1% | 65,295 | -49.6% | 3.03% | -40.9% |
| Q1 2017 | $3,990,000 | +2.5% | 129,548 | +11.5% | 5.12% | +6.7% |
| Q4 2016 | $3,891,000 | -20.1% | 116,153 | -36.6% | 4.80% | +22.6% |
| Q3 2016 | $4,872,000 | +18.3% | 183,086 | -2.0% | 3.91% | +11.5% |
| Q2 2016 | $4,120,000 | +31.7% | 186,850 | +75.4% | 3.51% | +42.0% |
| Q1 2016 | $3,128,000 | -62.9% | 106,508 | -58.3% | 2.47% | -18.1% |
| Q4 2015 | $8,428,000 | -39.8% | 255,227 | -34.1% | 3.02% | -31.7% |
| Q3 2015 | $13,995,000 | -29.6% | 387,234 | -12.3% | 4.42% | -10.7% |
| Q2 2015 | $19,874,000 | +46.1% | 441,739 | -0.6% | 4.95% | +53.5% |
| Q1 2015 | $13,605,000 | – | 444,328 | – | 3.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
| Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
| Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
| Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
| Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
| ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
| Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
| Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |